HealthcareServices

Glioblastoma Multiforme Market Performance Outlook 2026–2030: Revenue to Hit $3.93 Billion at 7.8% CAGR

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the glioblastoma multiforme market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Glioblastoma Multiforme Market covering 2026–2035?

The glioblastoma multiforme market has experienced strong growth in recent years. It is forecast to expand from $2.7 billion in 2025 to $2.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.1%. The market’s historic period growth stemmed from various elements such as limited treatment options, progress in neuro-oncology, chemotherapy standardization, an increase in cancer research centers, and improved imaging technologies.

The glioblastoma multiforme market is projected to witness significant expansion over the next few years. It is expected to grow to $3.94 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.8%. The anticipated growth during this period is largely driven by the creation of innovative targeted drugs, the broadening scope of immunotherapy research, the adoption of personalized cancer treatments, increased financial backing for brain cancer studies, and a greater focus on improving survival rates. Furthermore, prominent trends for the forecast period include a heightened emphasis on targeted cancer therapies, a growing reliance on multimodal treatment strategies, the expansion of precision oncology research, wider acceptance of advanced imaging diagnostics, and enhanced participation in clinical trials.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Glioblastoma Multiforme Market?

The future expansion of the glioblastoma multiforme market is anticipated to be fueled by the growing prevalence of brain disorder cases. A brain disorder refers to any condition impacting the brain’s structure or function, resulting in cognitive, emotional, or physical deficits. The increase in these cases is attributable to several factors, including an aging global populace, extended life expectancies, various lifestyle elements, and enhancements in diagnostic tools. Gaining insights into brain disorders facilitates progress in research concerning glioblastoma multiforme (GBM), leading to improved early detection, novel therapeutic approaches, and better patient results. Through the examination of neurological conditions, researchers can identify genetic and molecular connections crucial to the development of GBM. For example, in February 2025, Dementia Australia, an Australia-based non-profit organization, reported that around 433,300 Australians are currently living with dementia, a figure projected to reach 812,500 by 2054. Furthermore, younger-onset dementia affects approximately 29,000 individuals in 2025, with forecasts suggesting this number will climb to 41,000 by 2054. Consequently, the escalating number of brain disorder cases is poised to propel the growth of the glioblastoma multiforme market.

What Leading Segments Are Studied In The Glioblastoma Multiforme Market?

The glioblastoma multiforme market covered in this report is segmented –

1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes

2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools

3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types

4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites

2) By Temozolomide: Branded (Temodar), Generic Temozolomide

3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)

4) By Lomustine: Branded (Gleostine), Generic Lomustine

5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy

Which Trends Are Influencing The Development Of The Glioblastoma Multiforme Market?

Key companies operating within the glioblastoma multiforme market are concentrating on advancing therapies, such as CAR T-cell treatments, to address the unmet medical requirements of this aggressive cancer. CAR T-cell therapies represent an immunological approach that involves modifying a patient’s T-cells to more effectively target and eliminate cancer cells. For instance, in June 2023, Chimeric Therapeutics Limited, an Australian biotech company, commenced a Phase IB clinical trial of CHM 1101 (CLXT CAR T) therapy for recurrent or progressive glioblastoma multiforme (GBM). This multi-center trial is designed to assess the therapy’s safety and efficacy, while also identifying the recommended Phase 2 dose. Initial Phase 1a results demonstrated disease stability, and the trial aims to build upon these findings to support subsequent development. The company intends to utilize the data collected to design a registration trial and seek feedback from regulatory authorities.

Which Key Market Players Are Investing In Expansion And Innovation Within The Glioblastoma Multiforme Market?

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Which Regions Are Projected To Dominate The Glioblastoma Multiforme Market In The Coming Years?

North America was the largest region in the glioblastoma multiforme market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Glioblastoma Multiforme Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21191&type=smp

Browse Through More Reports Similar to the Global Glioblastoma Multiforme Market 2026, By The Business Research Company

Adult Malignant Glioma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Glioblastoma Multiforme Gbm Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-gbm-treatment-global-market-report

Glioma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795